Preece M A
Institute of Child Health, University College London Medical School, England.
J Pediatr. 1997 Jul;131(1 Pt 2):S61-4. doi: 10.1016/s0022-3476(97)70014-3.
Growth hormone (GH) has been available for therapeutic use for more than 30 years, but there is still considerable debate about the best way to diagnose GH deficiency. This can be attributed to the existence of a variable degree of GH insufficiency in most cases and the fact that assays vary considerably between laboratories in terms of sensitivity and epitope specificity. These difficulties are compounded by the episodic nature of GH secretion and our reliance on a variety of provocative tests. A workshop and consensus report held in Portland, Oregon, in 1995 highlighted these issues and suggested a rational diagnostic approach that emphasizes good auxologic evidence, followed by assays of insulin-like growth factor I and insulin-like growth factor binding protein 3 to identify abnormalities in the GH axis. Actual assays of GH, during some provocative tests, are relegated to confirming that an identified abnormality in the GH-insulin-like growth factor axis is related to GH insufficiency rather than to GH resistance.
生长激素(GH)用于治疗已有30多年,但关于诊断GH缺乏的最佳方法仍存在相当大的争议。这可归因于大多数情况下存在不同程度的GH分泌不足,以及各实验室的检测方法在灵敏度和表位特异性方面差异很大。GH分泌的间歇性以及我们对多种激发试验的依赖使这些困难更加复杂。1995年在俄勒冈州波特兰举行的一次研讨会及共识报告强调了这些问题,并提出了一种合理的诊断方法,该方法强调良好的体格学证据,随后检测胰岛素样生长因子I和胰岛素样生长因子结合蛋白3以确定GH轴的异常。在某些激发试验期间,实际的GH检测被用于确认GH-胰岛素样生长因子轴中已确定的异常与GH分泌不足有关,而非与GH抵抗有关。